

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/282834661>

Synthesis and Biological Evaluation of Novel 7-O-Lipophilic Substituted Baicalein Derivatives as Potential Anticancer Agents

ARTICLE *in* MEDICINAL CHEMISTRY COMMUNICATION · SEPTEMBER 2015

Impact Factor: 2.5 · DOI: 10.1039/C5MD00163C

READS

20

11 AUTHORS, INCLUDING:



[Shao-Hung Wang](#)

National Chiayi University

38 PUBLICATIONS 418 CITATIONS

[SEE PROFILE](#)



[Lih-Geeng Chen](#)

National Chiayi University

59 PUBLICATIONS 1,208 CITATIONS

[SEE PROFILE](#)



[Cheng-Deng Kuo](#)

Taipei Veterans General Hospital

140 PUBLICATIONS 1,527 CITATIONS

[SEE PROFILE](#)



[Jin-Yi Wu](#)

National Chiayi University

31 PUBLICATIONS 293 CITATIONS

[SEE PROFILE](#)

CONCISE ARTICLE



Cite this: *Med. Chem. Commun.*,
2015, 6, 1864

Synthesis and biological evaluation of novel 7-O-lipophilic substituted baicalein derivatives as potential anticancer agents†

Shao-Hung Wang,^a Ching-Hsein Chen,^a Chih-Yu Lo,^b Ji-Zhen Feng,^a Hong-Jhii Lin,^a Po-Ya Chang,^a Ling-Ling Yang,^c Lih-Geeng Chen,^a Yi-Wen Liu,^a Cheng-Deng Kuo^d and Jin-Yi Wu^{*a}

We synthesized derivatives of baicalein, wogonin, and chrysins through alkylation at the 7-O-position of the A ring with lipophilic terphenyl or long chain *n*-alkyl groups, and studied the *in vitro* anticancer activity of the derivatives through the growth inhibition MTT assay. We discovered that baicalein and two of its derivatives were good free radical scavengers. Among the 20 synthesized derivatives, 7-O-farnesylbaicalein (5d) and 7-O-dodecylbaicalein (5i) demonstrated stronger growth inhibition against human colon cancer SW480 cells compared with baicalein, with half maximal inhibitory concentration (IC_{50}) values of 1.15 and 1.57 μ M, respectively. Furthermore, 5d and 5i dose- and time-dependently inhibited the growth of SW480 cells. Cell cycle distribution analysis showed that 5d and 5i induced SW480 cell arrest at the S phase through an apoptotic mechanism, which was associated with an increase in the generation of reactive oxygen species. In conclusion, the potent anticancer activity of the baicalein derivatives (5d and 5i) suggested that the derivatives are potential anticancer agents for human colon cancer.

Received 20th April 2015,
Accepted 3rd September 2015

DOI: 10.1039/c5md00163c

www.rsc.org/medchemcomm

1. Introduction

Colorectal cancer (CRC) is the most commonly diagnosed cancer and is a leading cause of cancer mortality. It remains a considerable major health concern both globally¹ and in Taiwan, where the number of patients diagnosed with CRC has increased; such patients generally have a poor prognosis. Therapeutic strategies to treat CRC include surgery, chemotherapy, and radiation therapy;² however, the side effects associated with chemotherapy and radiation therapy, the high mortality rates and local tumour recurrence associated with surgical procedures^{3,4} necessitate alternative therapeutic options for CRC patients.

Flavonoids are a group of compounds found in several plant sources, such as citrus fruits, seeds, olive oil, and cocoa, as well as in tea and red wine.⁵ They are low-molecular-weight compounds containing a three-ring (polyphenolic) structure with various substituents.⁶ For decades, flavonoids have been utilized for their significant pharmacological activities, including anticancer activity.⁷ Studies have shown that flavonoids reduce the risk of cancer, inflammation, and heart diseases.⁸ Additional studies have demonstrated that flavonoids possess antioxidant, anti-inflammatory, anti-allergic, antiviral, and hepatoprotective properties.⁹ Both *in vitro* and *in vivo* xenograft models have shown that flavonoids are cytotoxic to various human cancer cell lines, suggesting their potential as anticancer agents.^{10–12}

Flavonoids are present in abundant quantities in traditional Chinese medicinal herbs, such as Huang-Qin (*Scutellaria baicalensis* Georgi). The four major flavonoids present in Huang-Qin are baicalein, baicalin, oroxylin A, and wogonin (Fig. 1). Baicalein is widely used as an antioxidant, anti-inflammatory, and anticancer agent.^{13,14} A hepatic metabolic study demonstrated that the bioavailability and effectiveness of baicalein decreased rapidly in the intestinal tract upon glucuronidation or sulfation of the hydroxyl group at the 7-O-position. More than 90% of baicalein is converted to baicalein-7-O-glucuronide (baicalin) in the intestines.^{15–17}

^a Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, 300 University Road, Chiayi 60004, Taiwan. E-mail: jywu@mail.nctu.edu.tw; Fax: +886 5 2717778;

Tel: +886 5 2717925

^b Department of Food Science, College of Life Sciences, National Chiayi University, Chiayi 60004, Taiwan

^c College of LOHAS, Fo Guang University, Yilan County 26247, Taiwan

^d Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei 11217, Taiwan

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5md00163c





Fig. 1 Chemical structures of baicalein (1), baicalin (2), wogonin (3), and chrysins (4).


Baicalein is a selective inhibitor of 12-lipoxygenase, which is responsible for the production of reactive oxygen species (ROS) during arachidonic acid metabolism.¹⁸ Shieh *et al.* demonstrated that baicalein acts as a strong scavenger of superoxide radicals in a cell-free system through rapid donation of hydrogen ions.¹⁹ Thus, these polyphenols may be vital in preventing human oxidative stress by scavenging hydroxyl, DPPH, and alkyl free radicals.^{20,21} Various methods, such as DPPH and ABTS⁺ radical scavenging, have been used to estimate the *in vitro* antioxidant activity of baicalein derivatives.

The other two flavonoid components isolated from *S. baicalensis* Georgi, oroxylin A and wogonin, have also been reported to possess anticancer properties.^{18–21}

The current study was conducted to determine whether baicalein derivatives with lipophilic moieties exhibit increased cell permeability and thus higher intracellular oxidative stress and cytotoxicity. We synthesized and evaluated a series of lipophilic substituted baicalein derivatives, with a focus on substitution at the 7-*O*-position of the A ring with terphenyl or long chain *n*-alkyl groups. Moreover, we



Scheme 1 Synthesis of 7-*O*-substituted baicalein derivatives. ^aReagents and conditions: (a) *n*-alkyl or terphenyl bromide, anhydrous K₂CO₃, anhydrous acetone, reflux, 8–24 h.



Scheme 2 Synthesis of 7-O-substituted wogonin and chrysin derivatives. ^aReagents and conditions: (a) methyl iodide or terphenyl bromide, anhydrous K₂CO₃, anhydrous acetone, reflux, 8–24 h.

examined the effects of the synthesized derivatives on cell proliferation, cell cycle progress, and apoptosis against three human colon cancer cell lines, one human liver cancer cell line, and one normal mouse liver cell line.

2. Chemistry

Derivatives of baicalein (1), wogonin (3), and chrysin (4) were synthesized through 7-O-alkylation with a long chain *n*-alkyl or terphenyl bromide. As shown in Schemes 1 and 2, 5a–i, 6a–d, and 7a–d were synthesized according to a procedure reported in the literature by reacting baicalein (1), wogonin (3), and chrysin (4) with selected *n*-alkyl or terphenyl bromides in anhydrous acetone using anhydrous potassium carbonate (K₂CO₃) as a base under N₂ for 8–24 h.¹⁴

In brief, the reaction mixture was refluxed for 8–24 h, and the progress of the reaction was monitored using TLC. Subsequently, the reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was chromatographed on a silica gel column and eluted with EtOAc/n-Hex (1/3) to afford the desired baicalein, wogonin, and chrysin derivatives (5a–i, 6a–d, and 7a–d, respectively) in 40.0–72.3% yields (Schemes 1 and 2). The 7-O-substituted derivatives were the major products and the 6,7-O-disubstituted derivatives were only minor products with yields less than 10%. The structures of the flavonoid derivatives were determined through ¹H and ¹³C NMR spectroscopy and liquid chromatography–mass spectrometry.

3. Results and discussion

3.1. Analysis of antioxidant activity of baicalein derivatives

The hydroxyl group of the A ring of baicalein was first alkylated at the 7-O-position with terphenyl or long chain *n*-alkyl groups, and the free-radical scavenging activity was examined using both DPPH and ABTS⁺ scavenging

methods.^{20,21} For comparison, the antioxidant activities of baicalein, oroxylin A, ascorbic acid and quercetin were analyzed. As shown in Table 1, a minor difference in DPPH and ABTS⁺ free radical activities was observed among analyzed derivatives.

3.2. Analysis of *in vitro* anti-proliferative activity using MTT assay

The cytotoxic activity of the synthesized derivatives was evaluated by *in vitro* growth inhibition assays using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).²² The derivatives were rated according to their half maximal inhibitory concentration values (IC₅₀), a measure of the effectiveness of a compound in inhibiting biological and biochemical functions; the lower the IC₅₀ value, the more effective the compound at inhibiting cancer cell growth. The

Table 1 Antioxidant effect of baicalein (1) and its derivatives (5a–i), trolox, ascorbic acid, and quercetin

Compound	IC ₅₀ (μ M) ^a (mean \pm SD)	
	DPPH	ABTS ⁺
Baicalein (1)	17.18 \pm 1.26	15.54 \pm 1.26
5a	28.40 \pm 2.06	20.22 \pm 1.36
5b	23.97 \pm 1.13	18.83 \pm 0.47
5c	24.34 \pm 1.56	20.43 \pm 1.66
5d	24.59 \pm 2.30	23.99 \pm 1.64
5e	12.91 \pm 0.57	13.98 \pm 0.45
5f	23.59 \pm 0.30	20.37 \pm 0.79
5g	21.53 \pm 0.29	20.27 \pm 1.50
5h	28.58 \pm 0.52	23.40 \pm 0.59
5i	23.51 \pm 0.60	26.27 \pm 1.85
Trolox	22.70 \pm 0.03	16.80 \pm 0.02
Ascorbic acid	27.30 \pm 0.05	18.30 \pm 0.55
Quercetin	8.41 \pm 0.64	7.26 \pm 0.01

^a Compound concentration required to inhibit the rate by 50%. Data are expressed as mean \pm SD from the dose-response curves of 3–5 independent experiments.

Table 2 clogP values and cytotoxic activities (IC_{50} , μM) of baicalein, wogonin, chrysins and their derivatives against four human cancer cell lines and one normal cell line after drug exposure for 48 h

Compound	clog P ^a	IC ₅₀ (μM) ^b (mean \pm SD)				
		SW480 ^c	HT-29 ^c	DLD-1 ^c	HepG2 ^d	BNL CL.2 ^e
Baicalein (1)	3.00	18.18 \pm 0.89	30.61 \pm 0.46	27.88 \pm 0.31	28.09 \pm 0.51	>40
5a	3.33	29.41 \pm 0.46	>40	30.93 \pm 0.65	>40	>40
5b	5.03	8.60 \pm 0.37	>20	>20	>20	>20
5c	7.06	2.84 \pm 0.43	17.02 \pm 0.25	9.77 \pm 0.93	>20	>20
5d	9.09	1.15 \pm 0.15	14.95 \pm 0.63	6.97 \pm 0.15	>20	>20
5e	4.92	>20	19.48 \pm 0.35	>20	>20	>20
5f	5.98	9.48 \pm 0.47	17.65 \pm 0.16	19.01 \pm 0.52	>20	>20
5g	7.03	3.03 \pm 0.46	16.25 \pm 0.62	15.41 \pm 0.76	>20	>20
5h	8.09	1.99 \pm 0.38	>20	15.52 \pm 0.47	>20	>20
5i	9.15	1.57 \pm 0.20	>20	9.26 \pm 0.10	>20	>20
Wogonin (3)	3.33	35.06 \pm 3.84	39.55 \pm 0.23	36.87 \pm 0.65	37.89 \pm 2.26	>40
6a	3.77	>20	>20	>20	2.72 \pm 0.84	>20
6b	5.48	>20	>20	>20	>20	>20
6c	7.51	>20	>20	>20	>20	>20
6d	9.54	>20	>20	>20	>20	>20
Chrysins (4)	3.56	31.08 \pm 2.96	19.49 \pm 0.38	18.62 \pm 0.81	16.50 \pm 0.36	>40
7a	4.15	>20	>20	>20	>20	>20
7b	5.85	>20	>20	>20	>20	>20
7c	7.88	>20	>20	>20	>20	>20
7d	9.91	>20	>20	>20	>20	>20
Cisplatin		40.72 \pm 1.18	24.07 \pm 0.03	— ^f	36.07 \pm 3.11	—
5-Fu		32.72 \pm 8.32	>100	—	40.18 \pm 7.63	—
Doxorubicin		0.53 \pm 0.07	1.70 \pm 0.20	—	0.30 \pm 0.02	—

^a Calculated log value of partition coefficient by ChemDraw Ultra 11.0. ^b Compound concentration (μM) required to inhibit the tumor cell proliferation rate by 50%. Data are expressed as mean \pm SD from the dose-response curves of 3–5 independent experiments. ^c Human colon adenocarcinoma cell lines. ^d Human hepatocarcinoma cell lines. ^e Normal murine embryonic liver cell lines. ^f Not tested.

cytotoxic activities of 20 flavonoid derivatives, along with those of 5-fluorouracil (5-Fu), cisplatin, and doxorubicin as positive controls, were examined against four human cancer cell lines, including SW480 (colon carcinoma), HT29 (colon carcinoma), DLD-1 (colon carcinoma), and HepG2 (liver carcinoma), and one normal murine embryonic liver cell line (BNL CL.2). The clogP and IC_{50} values of the tested compounds are listed in Table 2. The anticancer activity of the derivatives increased with the chain length, or lipophilic characteristics, of the substituents. The lipophilic activity was evident in two striking bioactive derivatives, namely 7-O-farnesylbaicalein (5d) and 7-O-dodecylbaicalein (5i). Both showed significant cell growth inhibition in all four human cancer cell lines with IC_{50} values of 1.15 ± 0.15 and $1.57 \pm 0.20 \mu\text{M}$, respectively, against the SW480 cell line. These values were 16- to 11-fold more active compared with baicalein (1), which exhibited an IC_{50} value of $18.18 \pm 0.89 \mu\text{M}$. When treated with baicalein (1), 5d, or 5i, no significant cell death was detected in the normal murine embryonic liver BNL CL.2 cell line. Furthermore, only a marked effect on cell death (<20%) was observed at the highest concentration tested (20 μM) for 5d and 5i after 48 h of treatment. Baicalein (1) exhibited a slight cytotoxic effect after 48 h, suggesting that both 5d and 5i were cytotoxic to human colon cancer cells with no significant adverse effects on normal murine embryonic liver cells.

In the light of the cytotoxicity-related findings described previously, we examined the cytotoxicity of 5d and 5i against

SW480 cells as a function of time. As shown in Table 3, the *in vitro* cytotoxicity of 5d and 5i demonstrated a 12- and 8-fold increase on SW480 cells for 48 h treatment, respectively, compared with baicalein (1) (Fig. 2).

We hypothesized that the increased activity of the synthesized derivatives is attributable to their enhanced bioavailability and cell membrane permeability which resulted from the increased lipophilicity. To investigate this hypothesis, we calculated the clogP values of the 7-O-substituted baicalein derivatives and compared their anticancer activity. The clogP values correlated satisfactorily with the IC_{50} values (Table 3). Hence, these results support our hypothesis that the lipophilicity, or the chain length, of the *n*-dodecyl and farnesyl moieties of the 7-O-substituted baicalein derivatives played a vital role in the anticancer activity of those derivatives.

3.3. Cell morphological assessment

Cell apoptosis was observed by examining Hoechst 33258 stained cell nuclei through fluorescence microscopy. Apoptosis was determined as changes in cell morphology, such as chromatin condensation, nuclear shrinkage, and DNA fragmentation.²³ To further investigate the role of apoptosis in the cytotoxicity of 5d and 5i, SW480 cells were incubated with 20 μM baicalein (1), 5d, or 5i, and in 0.1% DMSO as control, for 48 h. The cells were stained with Hoechst 33258 and examined using fluorescence microscopy for topical morphological changes. The nuclei of the cells in the control sample




Fig. 2 *In vitro* cytotoxicity of (A) baicalein (1), (B) 5d, and (C) 5i in SW480 cells after drug exposure over various time periods.

were round and stained homogenously, whereas those treated with baicalein (1), 5d, and 5i exhibited typical morphological features of apoptosis such as nuclear shrinkage, chromatin condensation and DNA fragmentation (Fig. 3).²⁴ These results demonstrated that 5d and 5i induced apoptosis in SW480 cells.

3.4. Cell cycle distribution analysis through flow cytometry

To analyze the apoptotic effects of baicalein (1), 5d, and 5i on cell cycle progression, SW480 cells were treated with the synthesized derivatives at different concentrations for 48 h. The cell cycle distribution and the SubG1 phase were analyzed through flow cytometry after propidium iodide (PI) staining.²⁵ Untreated cells were used as the control. The percentage of cells at the S phase increased by 33.33% and 50.00% when treated with 10 and 20 μM 5d, respectively, and by 32.12% and 51.02% when treated with 10 and 20 μM 5i, respectively, as compared with the 26.19% increase in the control (Fig. 4). The increased percentage of cells at the S phase and the cytotoxic activity of 5d and 5i suggested that the synthesized derivatives induced SW480 cell arrest in the S phase. In addition, baicalein was also found to increase the percentage of cells at the S phase after the 24 h exposure at a concentration of 50 μM for the test compounds. Analysis of the S-phase arrest, however, showed that the concentration of all cell cycle regulatory molecules, cyclin-dependent kinase 4 (CDK4), cyclin B1, and cyclin D1, showed a decreased level.²⁶ Our results indicated that baicalein did not affect the cell cycle in the SW480 cells. A study²⁶ showed that baicalein dose-dependently inhibited the growth of human lung squamous carcinoma CH27 cells. The results of the current study may suggest that the apoptotic effect of baicalein depends on the type of cancer cells under treatment.

3.5. Annexin V-FITC/PI staining

To study the bioactivity of baicalein (1), 5d, and 5i against SW480 cells, the cancer cells were treated with vehicle alone as control, or with one of the three test compounds, at different concentrations (5, 10, and 20 μM). After 48 h, the samples were double-stained with annexin V-FITC and PI.²⁷ The percentages of cells at various stages of apoptosis are shown in Fig. 5. The data indicated that the apoptotic cell death resulting from treatment with 5d or 5i was dose-dependent; however, this was not observed in cells treated with baicalein (1). Starting from a dose of 10 μM, both 5d and 5i induced a higher degree of apoptosis in SW480 cells compared with baicalein (1) and cytotoxic effects at both the early and late stages, as determined through annexin V-FITC/PI staining. For baicalein (1), the effect was observed only at a higher concentration (20 μM). The analysis confirmed the superior efficiency of both 5d and 5i in inducing cytotoxicity and inhibiting the proliferation of human colorectal cancer cells.

3.6. Measurement of intracellular ROS production

Several flavonoids induce apoptosis by generating reactive oxygen species (ROS) in mitochondria.²⁸ Baicalein and its derivatives are hypothesized to induce apoptosis by increasing the concentration of intracellular ROS. Therefore, we investigated whether baicalein (1), 5d, or 5i could stimulate the generation of ROS in SW480 cells. The fluorescence

Table 3 *In vitro* cytotoxicity of baicalein (**1**), **5d**, and **5i** against a panel of human colon cancer cell lines over various time periods

Compound	IC_{50} (μ M) ^a (mean \pm SD)								
	SW480 ^b			HT-29 ^b			DLD-1 ^b		
	24 h	48 h	72 h	24 h	48 h	72 h	24 h	48 h	72 h
Baicalein (1)	16.95 \pm 0.47	14.05 \pm 1.09	11.55 \pm 2.63	>20	18.05 \pm 1.68	18.36 \pm 2.98	>20	>20	>20
5d	>20	1.21 \pm 0.03	1.26 \pm 0.13	>20	16.80 \pm 0.68	15.40 \pm 0.46	16.15 \pm 1.02	4.88 \pm 0.58	6.86 \pm 2.59
5i	>20	1.84 \pm 0.08	1.64 \pm 0.58	>20	>20	>20	>20	7.23 \pm 1.42	6.19 \pm 1.71

^a Compound concentration required to inhibit the tumor cell proliferation rate by 50%. Data are expressed as mean \pm SD from the dose-response curves of 3–5 independent experiments. ^b Human colon adenocarcinoma cell lines.




Fig. 3 Morphological changes in SW480 cells treated with baicalein (**1**), **5d**, or **5i** at 20 μ M for 48 h (magnification, 200 \times). The upper panels show the cell morphology under phase contrast microscopy, and the lower panels display the Hoechst 33258-stained nuclear patterns detected through fluorescence microscopy (magnification, 200 \times). Red arrows indicate the apoptotic cells.

intensity of dihydroethidium (DHE) in the cells was right-shifted after the cells were treated with all three compounds in a concentration-dependent manner (Fig. 6), indicating that both **5d** and **5i** could stimulate the release of intracellular O₂[−] from SW480 cells. As expected, **5d** and **5i**, at concentrations of 5, 10, and 20 μ M, exhibited a more profound effect (mean values = 102.13, 169.24, and 192.86, respectively, for **5d**; mean values = 117.62, 165.78, and 215.12, respectively, for **5i**) compared with baicalein (mean values = 104.84, 99.49, and 98.79, respectively) on O₂[−] generation in SW480 cells after 48 h of treatment ($P < 0.05$, Fig. 6B). Thus, the results showed that **5d** and **5i** induced apoptosis by increasing the intracellular oxidative stress of SW480 cells, and exhibited a strong capacity to induce apoptosis in SW480 cells in a ROS-dependent manner.

4. Conclusions

Among the 20 analyzed derivatives, baicalein derivatives **5d** and **5i**, which have a farnesyl group and a dodecyl group at the 7-O-position, respectively, showed a superior level of cytotoxicity against all human cancer cell lines studied. Furthermore, we discovered that **5d** and **5i** were the most cytotoxic *in vitro*, against human colon adenocarcinoma SW480 cells. In the cell cycle distribution and apoptotic analysis, **5d** and **5i** induced SW480 cell arrest at the S phase. In the Hoechst 33258 staining analysis, **5d** and **5i** markedly induced apoptosis, which was confirmed by the positive rate of annexin V-FITC/PI double staining. Both derivatives induced apoptosis in SW480 cells, by inducing ROS generation. The results indicate that **5d** and **5i** exhibit an enhanced anticancer activity against human colon cancer cells compared with standard treatments.




Fig. 4 Effect of baicalein (**1**) and its derivatives on SW480 cell cycle distribution. (A) Cell cycle distribution after treatment with baicalein (**1**), **5d**, or **5i** at 5–20 μM in SW480 cells for 48 h. (B) Quantitative difference of cell cycle distribution changed after treatment with baicalein (**1**), **5d**, and **5i** at 5–20 μM in SW480 for 48 h. Data are shown as mean \pm SD of three independent experiments, and * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ compared with control.



A**B**

Fig. 5 Effect of baicalein (1), 5d, or 5i on cell apoptosis and necrosis of SW480 cells assessed through flow cytometry. (A) Analysis of the cell death pathway after treatment with baicalein (1), 5d, or 5i at 5–20 μ M in SW480 cells for 48 h. (B) Quantitative analysis of the cell death pathway after treatment with baicalein (1), 5d, and 5i at 5–20 μ M in SW480 cells for 48 h. The plates were examined for apoptotic cells using an Annexin V-FITC apoptosis detection kit. Annexin V-positive/PI-negative cells are found in the early stages of apoptosis and double positive cells are found in the late stages of apoptosis, whereas Annexin V-negative/PI-positive cells are necrotic. Each value represents the mean \pm SD of three independent experiments. * $P < 0.05$, compared with control.



A**B**

Fig. 6 Effect of baicalein (**1**), **5d**, or **5i** on ROS (O_2^-) generation in SW480 cells. (A) Analysis after treatment with baicalein (**1**), **5d**, or **5i** at 5–20 μM in SW480 cells for 48 h to detect O_2^- content. (B) Quantitative analysis after treatment with baicalein (**1**), **5d**, or **5i** at 5–20 μM in SW480 cells for 48 h to detect O_2^- content. Data are shown as mean \pm SD of three independent experiments, and $*P < 0.05$, compared with control.

Acknowledgements

The authors thank Dr. Christopher Liu for his valuable editorial revision. This study was supported by grants from Taipei Veterans General Hospital, Taiwan (V103E2-002 and V104E2-002).

Notes and references

- 1 WHO Report, <http://www.who.int/mediacentre/factsheets/fs297/en/index.html>.
- 2 A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, *Ca-Cancer J. Clin.*, 2011, **61**, 69–90.
- 3 S. Carnesecchi, K. Langley, F. Exinger, F. Gosse and F. Raul, *J. Pharmacol. Exp. Ther.*, 2002, **301**, 625–630.
- 4 M. Line-Edwige, F. Raymond, E. Francois and N. E. Edouard, *Afr. J. Tradit., Complementary Altern. Med.*, 2009, **6**, 112–117.
- 5 K. A. Youdim, J. P. E. Spencer, H. Schroeter and C. Rice-Evans, *Biol. Chem.*, 2005, **383**, 503–519.
- 6 A. Pick, H. Müller, R. Mayer, B. Haenisch, I. K. Pajeva, M. Weigt, H. Bönisch, C. E. Müller and M. Wiese, *Bioorg. Med. Chem.*, 2011, **19**, 2090–2102.
- 7 M. López-Lázaro, *Curr. Med. Chem.: Anti-Cancer Agents*, 2002, **2**, 691–714.
- 8 E. J. Middleton, C. Kandaswami and T. C. Theoharides, *Pharmacol. Rev.*, 2000, **52**, 673–751.
- 9 O. A. Aiyejoro and A. I. Okoh, *Int. J. Mol. Sci.*, 2009, **10**, 4990–5001.
- 10 R. J. Nijveldt, E. van Nood, D. E. van Hoorn, P. G. Boelens, K. van Norren and P. A. van Leeuwen, *Am. J. Clin. Nutr.*, 2001, **74**, 418–425.
- 11 Y. Suh, F. Afaq, J. J. Johnson and H. Mukhtar, *Carcinogenesis*, 2009, **30**, 300–307.
- 12 H. L. Liu, W. B. Jiang and M. X. Xie, *Recent Pat. Anti-Cancer Drug Discovery*, 2010, **5**, 152–164.
- 13 Z. Gao, K. Huang, X. Yang and H. Xu, *Biochim. Biophys. Acta*, 1999, **1472**, 643–650.
- 14 J. Y. Wu, K. T. Chung, Y. W. Liu, F. J. Lu, R. S. Tsai, C. H. Chen and C. H. Chen, *J. Agric. Food Chem.*, 2008, **56**, 2838–2845.
- 15 C. Li, L. Zhang, L. Zhou, S. K. Wo, G. Lin and Z. Zuo, *AAPS J.*, 2012, **14**, 23–34.
- 16 L. Zhang, G. Lin, B. Kovács, M. Jani, P. Krajesi and Z. Zuo, *Eur. J. Pharm. Sci.*, 2007, **31**, 221–231.
- 17 L. Zhang, G. Lin and Z. Zuo, *Pharm. Res.*, 2007, **24**, 81–89.
- 18 K. Sekiya and H. Okuda, *Biochem. Biophys. Res. Commun.*, 1982, **105**, 1090–1095.
- 19 D. E. Shieh, L. T. Liu and C. C. Lin, *Anticancer Res.*, 2000, **20**, 2861–2865.
- 20 T. Yamaguchi, H. Takamura, T. Matoba and J. Terao, *Biosci., Biotechnol., Biochem.*, 1998, **62**, 1201–1204.
- 21 R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang and C. Rice-Evans, *Free Radicals Biol. Med.*, 1999, **26**, 1231–1237.
- 22 T. Mosmann, *J. Immunol. Methods*, 1983, **65**, 55–63.
- 23 C. Y. Lo, L. C. Hsu, M. S. Chen, Y. J. Lin, L. G. Chen, C. D. Kuo and J. Y. Wu, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 305–309.
- 24 H. B. Zhang, P. Lu, Q. Y. Guo, Z. H. Zhang and X. Y. Meng, *Oncol. Lett.*, 2013, **5**, 722–728.
- 25 S. J. Kim, H. J. Kim, H. R. Kim, S. H. Lee, S. D. Cho, C. S. Choi, J. S. Nam and J. Y. Jung, *Mol. Med. Rep.*, 2012, **6**, 1443–1449.
- 26 H. Z. Lee, H. W. Leung, M. Y. Lai and C. H. Wu, *Anticancer Res.*, 2005, **5**, 959–964.
- 27 R. Luo, J. Wang, L. Zhao, N. Lu, Q. You, Q. Guo and Z. Li, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 1334–1338.
- 28 L. Burnaugh, K. Sabeur and B. A. Ball, *Theriogenology*, 2007, **67**, 580–589.